Q BioMed Inc CEO Denis Corin tells Proactive it has engaged EVERSANA, the pioneer of next-generation commercial services to the global life sciences industry, to immediately support the commercialization of Strontium89. Corin says Strontium89 to support and accelerate the product's rollout in the US, Q BioMed said it will leverage the EVERSANA COMPLETE Commercialization model which fully integrates services for market access, agency services, clinical and commercial field teams, health economics, and outcomes in research and compliance.
Q BioMed to forms partnership with EVERSANA to help commercialize Strontium89
